Rapid Antiretroviral Therapy Initiation Reduces Mortality Among People Living With HIV in Indonesia: A Retrospective Observational Study.

IF 2.1
Ifael Yerosias Mauleti, Krishna Adi Wibisana, Djati Prasetio Syamsuridzal, Sri Mulyati, Vivi Lisdawati, Harimat Hendarwan, Ika Saptarini
{"title":"Rapid Antiretroviral Therapy Initiation Reduces Mortality Among People Living With HIV in Indonesia: A Retrospective Observational Study.","authors":"Ifael Yerosias Mauleti, Krishna Adi Wibisana, Djati Prasetio Syamsuridzal, Sri Mulyati, Vivi Lisdawati, Harimat Hendarwan, Ika Saptarini","doi":"10.3961/jpmph.24.622","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Current recommendations for managing human immunodeficiency virus (HIV) propose that initiating antiretroviral therapy (ART) promptly after diagnosis, regardless of CD4 cell count, may decrease illness and mortality risk. This study aimed to investigate factors associated with reduced mortality, including the time to ART initiation after diagnosis with HIV.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the medical records of 326 people living with human immunodeficiency virus (PLHIV) aged 18 years or older who initiated ART at a tertiary hospital between January 2018 and December 2022. We employed Cox regression models to estimate survival and identify mortality predictors, considering variables with p-values less than 0.05 as statistically significant.</p><p><strong>Results: </strong>From 2018 to 2022, 19.9% of PLHIV initiated ART within 7 days of diagnosis, and 57 participants died. The final multivariable Cox proportional hazards model indicated that earlier ART initiation significantly reduced mortality risk compared with starting ART more than 60 days after diagnosis, with adjusted hazard ratios of 0.36 for initiation within 7 days and 0.42 for initiation between 8 days and 60 days. Additional characteristics associated with reduced mortality risk included a CD4 count above 200 cells/mm 3 before ART initiation, a lower World Health Organization clinical stage, and tuberculosis post-exposure prophylaxis.</p><p><strong>Conclusions: </strong>Earlier ART initiation significantly lowered mortality rates. Furthermore, a pre-ART CD4 count above 200 cells/mm3, a lower clinical stage, and tuberculosis preventive therapy were associated with reduced mortality risk among PLHIV. Future studies should investigate additional predictors of mortality within a prospective cohort study framework.</p>","PeriodicalId":520687,"journal":{"name":"Journal of preventive medicine and public health = Yebang Uihakhoe chi","volume":"58 4","pages":"360-369"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12332387/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of preventive medicine and public health = Yebang Uihakhoe chi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3961/jpmph.24.622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Current recommendations for managing human immunodeficiency virus (HIV) propose that initiating antiretroviral therapy (ART) promptly after diagnosis, regardless of CD4 cell count, may decrease illness and mortality risk. This study aimed to investigate factors associated with reduced mortality, including the time to ART initiation after diagnosis with HIV.

Methods: We conducted a retrospective cohort study using the medical records of 326 people living with human immunodeficiency virus (PLHIV) aged 18 years or older who initiated ART at a tertiary hospital between January 2018 and December 2022. We employed Cox regression models to estimate survival and identify mortality predictors, considering variables with p-values less than 0.05 as statistically significant.

Results: From 2018 to 2022, 19.9% of PLHIV initiated ART within 7 days of diagnosis, and 57 participants died. The final multivariable Cox proportional hazards model indicated that earlier ART initiation significantly reduced mortality risk compared with starting ART more than 60 days after diagnosis, with adjusted hazard ratios of 0.36 for initiation within 7 days and 0.42 for initiation between 8 days and 60 days. Additional characteristics associated with reduced mortality risk included a CD4 count above 200 cells/mm 3 before ART initiation, a lower World Health Organization clinical stage, and tuberculosis post-exposure prophylaxis.

Conclusions: Earlier ART initiation significantly lowered mortality rates. Furthermore, a pre-ART CD4 count above 200 cells/mm3, a lower clinical stage, and tuberculosis preventive therapy were associated with reduced mortality risk among PLHIV. Future studies should investigate additional predictors of mortality within a prospective cohort study framework.

Abstract Image

Abstract Image

Abstract Image

迅速开始抗逆转录病毒治疗可降低印度尼西亚艾滋病毒感染者的死亡率:一项回顾性观察研究。
目的:目前关于管理人类免疫缺陷病毒(HIV)的建议表明,在诊断后立即开始抗逆转录病毒治疗(ART),无论CD4细胞计数如何,都可能降低疾病和死亡风险。本研究旨在探讨与降低死亡率相关的因素,包括诊断为HIV后开始抗逆转录病毒治疗的时间。方法:我们进行了一项回顾性队列研究,使用了2018年1月至2022年12月期间在一家三级医院接受抗逆转录病毒治疗的326名18岁或以上的人类免疫缺陷病毒(PLHIV)感染者的医疗记录。我们采用Cox回归模型来估计生存率和确定死亡率预测因子,认为p值小于0.05的变量具有统计学意义。结果:2018年至2022年,19.9%的PLHIV患者在诊断后7天内开始抗逆转录病毒治疗,57名参与者死亡。最终的多变量Cox比例风险模型显示,与诊断后超过60天开始抗逆转录病毒治疗相比,更早开始抗逆转录病毒治疗可显著降低死亡风险,7天内开始抗逆转录病毒治疗的调整风险比为0.36,8天至60天开始抗逆转录病毒治疗的调整风险比为0.42。与降低死亡风险相关的其他特征包括:开始抗逆转录病毒治疗前CD4细胞计数高于200细胞/mm 3、较低的世界卫生组织临床分期和接触后结核病预防。结论:早期开始抗逆转录病毒治疗可显著降低死亡率。此外,抗逆转录病毒治疗前CD4细胞计数高于200细胞/mm3、较低的临床阶段和结核病预防治疗与降低PLHIV患者的死亡风险相关。未来的研究应在前瞻性队列研究框架内调查更多的死亡率预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信